Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5H8V1)

Drug Name
PF-06826647 Drug Info
Synonyms
Tyk2-IN-8; 2127109-84-4; Tyk2-IN-9; (1r,3r)-3-(Cyanomethyl)-3-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-1H-pyrazol-1-yl)cyclobutane-1-carbonitrile; Ropsacitinib; Ropsacitinib [USAN]; UNII-HY5SOV7O0Q; HY5SOV7O0Q; CHEMBL4459585; SCHEMBL19253418; SCHEMBL19253420; SCHEMBL19271747; SCHEMBL19276506; BDBM305820; BDBM305821; BCP33615; EX-A4020; US10144738, Example 19; US10144738, Example 20; MFCD32197240; s9676; WHO 11834; HY-126290A; HY-126290; CS-0101462; CS-0114967; (1s,3s)-3-(Cyanomethyl)-3-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-1H-pyrazol-1-yl)cyclobutane-1-carbonitrile; Cyclobutaneacetonitrile, 3-cyano-1-(4-(6-(1-methyl-1H-pyrazol-4- yl)pyrazolo(1,5-a)pyrazin-4-yl)-1H-pyrazol-1-yl)-, trans-; trans-3-(Cyanomethyl)-3-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-1H-pyrazol-1-yl)cyclobutanecarbonitrile; trans-3-Cyano-1-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo(1,5-a)pyrazin-4-yl)- 1H-pyrazol-1-yl)-cyclobutaneacetonitrile
Indication
Disease Entry ICD 11 Status REF
Plaque psoriasis EA90.0 Phase 2 [1]
Cross-matching ID
PubChem CID
130339268
CAS Number
CAS 2127109-84-4
TTD Drug ID
DM5H8V1

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting TYK2 tyrosine kinase (TYK2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Deucravacitinib DMAR1YS Plaque psoriasis EA90.0 Approved [2]
PF-06700841 DMMGSFV Asthma CA23 Phase 2 [2]
NDI-034858 DM2FJE7 Psoriatic arthritis FA21 Phase 2 [3]
Pyrazolo[4,3-c]pyridine derivative 2 DMCDFLQ N. A. N. A. Patented [4]
PMID27774824-Compound-Figure9Example2down DMXAV42 N. A. N. A. Patented [4]
Aminotriazolopyridine derivative 1 DMW2LZ0 N. A. N. A. Patented [4]
Imidazo[4,5-c]pyridine derivative 2 DMFDRJT N. A. N. A. Patented [4]
PMID27774824-Compound-Figure11Example1up DMH1W8F N. A. N. A. Patented [4]
Imidazo[4,5-c]pyridine derivative 1 DM4KBZQ N. A. N. A. Patented [4]
PMID27774824-Compound-Figure9Example2up DME3TMS N. A. N. A. Patented [4]
Deucravacitinib DMAR1YS Plaque psoriasis EA90.0 Approved [2]
PF-06700841 DMMGSFV Asthma CA23 Phase 2 [2]
NDI-034858 DM2FJE7 Psoriatic arthritis FA21 Phase 2 [3]
Pyrazolo[4,3-c]pyridine derivative 2 DMCDFLQ N. A. N. A. Patented [4]
PMID27774824-Compound-Figure9Example2down DMXAV42 N. A. N. A. Patented [4]
Aminotriazolopyridine derivative 1 DMW2LZ0 N. A. N. A. Patented [4]
Imidazo[4,5-c]pyridine derivative 2 DMFDRJT N. A. N. A. Patented [4]
PMID27774824-Compound-Figure11Example1up DMH1W8F N. A. N. A. Patented [4]
Imidazo[4,5-c]pyridine derivative 1 DM4KBZQ N. A. N. A. Patented [4]
PMID27774824-Compound-Figure9Example2up DME3TMS N. A. N. A. Patented [4]
⏷ Show the Full List of 20 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
TYK2 tyrosine kinase (TYK2) TTBYWP2 TYK2_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT03210961) A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of Nimbus Therapeutics
4 Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.